Mydecine Innovations Group Inc. (C:MYCO*CA)
Business Focus: Biotechnology & Medical Research (NEC)
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| Company Contact | |
| Address: | 1890-1075 West Georgia Street VANCOUVER BC V6E 3C9 |
| Tel: | N/A |
| Website: | https://www.mydecine.com |
| IR: | See website |
| Key People | ||
| David Joshua Bartch President, Chief Executive Officer, Director | John Ross Chief Financial Officer | Damon Michaels Chief Operating Officer |
| Robert Roscow Chief Scientific Officer, Director | Rakesh Jetly Chief Medical Officer | |
| Business Overview |
| Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company's principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval. |
| Financial Overview |
| For the nine months ended 30 September 2023, Mydecine Innovations Group Inc revenues was not reported. Net loss before extraordinary items increased 7% to C$12M. Higher net loss reflects Consulting fees increase of 20% to C$3.6M (expense), Corporate development increase from C$141K to C$504K (expense), Regulatory and filing fees increase from C$52K to C$151K (expense). |
| Employees: | 3 as of Dec 31, 2022 |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $1.39M as of Sep 30, 2023 |
| Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
| EBITDA (TTM): | -$13.57M as of Sep 30, 2023 |
| Net annual income (TTM): | -$18.07M as of Sep 30, 2023 |
| Free cash flow (TTM): | -$6.42M as of Sep 30, 2023 |
| Net Debt Last Fiscal Year: | $5.49M as of Sep 30, 2023 |
| Shares outstanding: | 61,755,385 as of Apr 16, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.